{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:08:32Z","timestamp":1791108512108,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.vph.2014.05.011","type":"journal-article","created":{"date-parts":[[2014,6,9]],"date-time":"2014-06-09T06:00:25Z","timestamp":1402293625000},"page":"103-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges"],"prefix":"10.1016","volume":"62","author":[{"given":"Giuseppe Danilo","family":"Norata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Tibolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico Luigi","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2014.05.011_bb0460","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2014.05.011_bb0010","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/eurheartj\/eht088","article-title":"New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs","volume":"34","author":"Norata","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2014.05.011_bb0465","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2014.05.011_bb0020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.vph.2014.05.011_bb0025","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.numecd.2011.06.002","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): from structure\u2013function relation to therapeutic inhibition","volume":"21","author":"Tibolla","year":"2011","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.vph.2014.05.011_bb0030","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2014.05.011_bb0035","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vph.2014.05.011_bb0040","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.vph.2014.05.011_bb0045","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2014.05.011_bb0050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-pharmtox-011613-140025","article-title":"Targeting PCSK9 for hypercholesterolemia","volume":"54","author":"Norata","year":"2014","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.vph.2014.05.011_bb0470","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.vph.2014.03.004","article-title":"Risk prediction with proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment","volume":"62","author":"Werner","year":"2014","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.vph.2014.05.011_bb0060","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vph.2014.05.011_bb0065","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.05.011_bb0070","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.0703402104","article-title":"The self-inhibited structure of full-length PCSK9 at 1.9A reveals structural homology with resistin within the C-terminal domain","volume":"104","author":"Hampton","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vph.2014.05.011_bb0075","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.vph.2014.05.011_bb0080","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1194\/jlr.M700071-JLR200","article-title":"Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis","volume":"48","author":"Qian","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vph.2014.05.011_bb0085","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1600-0854.2007.00562.x","article-title":"The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR","volume":"8","author":"Nassoury","year":"2007","journal-title":"Traffic"},{"key":"10.1016\/j.vph.2014.05.011_bb0090","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vph.2014.05.011_bb0095","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.05.011_bb0100","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1074\/jbc.M808363200","article-title":"Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants","volume":"284","author":"Bottomley","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.05.011_bb0105","doi-asserted-by":"crossref","first-page":"13045","DOI":"10.1073\/pnas.0806312105","article-title":"Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.vph.2014.05.011_bb0475","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1074\/jbc.M110.199042","article-title":"A two step binding model of PCSK9 interaction with the low density lipoprotein receptor","volume":"286","author":"Yamamoto","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.05.011_bb0115","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1194\/jlr.M018093","article-title":"Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors","volume":"52","author":"Holla","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vph.2014.05.011_bb0120","doi-asserted-by":"crossref","first-page":"10805","DOI":"10.1074\/jbc.M113.453373","article-title":"Characterization of proprotein convertase subtilisin\/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2)","volume":"288","author":"DeVay","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.05.011_bb0125","doi-asserted-by":"crossref","first-page":"e00444","DOI":"10.7554\/eLife.00444","article-title":"SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion","volume":"2","author":"Chen","year":"2013","journal-title":"eLife"},{"key":"10.1016\/j.vph.2014.05.011_bb0130","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cmet.2013.12.006","article-title":"The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion","volume":"19","author":"Gustafsen","year":"2014","journal-title":"Cell Metab"},{"issue":"12","key":"10.1016\/j.vph.2014.05.011_bb0480","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1074\/jbc.M112.421370","article-title":"Low-density lipoprotein binds to proprotein convertase subtilisin\/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated LDL receptor degradation","volume":"288","author":"Kosenko","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.05.011_bb0140","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/ATVBAHA.112.250043","article-title":"Proprotein convertase subtilisin\/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor","volume":"32","author":"Sun","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2014.05.011_bb0145","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2011.11.026","article-title":"Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels","volume":"220","author":"Ferri","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2014.05.011_bb0150","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1194\/jlr.M014118","article-title":"PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke","volume":"52","author":"Rousselet","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vph.2014.05.011_bb0155","doi-asserted-by":"crossref","first-page":"31791","DOI":"10.1074\/jbc.M805971200","article-title":"Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels","volume":"283","author":"Mayer","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.05.011_bb0160","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/ATVBAHA.110.214130","article-title":"Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans","volume":"30","author":"Persson","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2014.05.011_bb0165","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1194\/jlr.M700443-JLR200","article-title":"Sterol-dependent regulation of proprotein convertase subtilisin\/kexin type 9 expression by sterol-regulatory element binding protein-2","volume":"49","author":"Jeong","year":"2008","journal-title":"J Lipid Res"},{"issue":"6","key":"10.1016\/j.vph.2014.05.011_bb0485","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1074\/jbc.M110.192104","article-title":"In vivo evidence that furin from hepatocytes inactivates PCSK9","volume":"286","author":"Essalmani","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.05.011_bb0175","doi-asserted-by":"crossref","first-page":"43482","DOI":"10.1074\/jbc.M112.380618","article-title":"Furin-cleaved proprotein convertase subtilisin\/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels","volume":"287","author":"Lipari","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.05.011_bb0180","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.vph.2014.05.011_bb0185","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.vph.2014.05.011_bb0190","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.atherosclerosis.2010.09.027","article-title":"Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population","volume":"213","author":"Cui","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2014.05.011_bb0195","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method for measurement of total plasma PCSK9: clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vph.2014.05.011_bb0200","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1373\/clinchem.2011.172932","article-title":"Rosuvastatin, proprotein convertase subtilisin\/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial","volume":"58","author":"Awan","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.vph.2014.05.011_bb0205","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9","volume":"49","author":"Careskey","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vph.2014.05.011_bb0210","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vph.2014.05.011_bb0215","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1373\/clinchem.2007.099747","article-title":"Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment","volume":"54","author":"Lambert","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.vph.2014.05.011_bb0220","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1194\/jlr.M000620","article-title":"Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels","volume":"51","author":"Troutt","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vph.2014.05.011_bb0225","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.atherosclerosis.2010.05.027","article-title":"Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients","volume":"212","author":"Costet","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2014.05.011_bb0230","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1194\/jlr.P009860","article-title":"Fasting reduces plasma proprotein convertase, subtilisin\/kexin type 9 and cholesterol biosynthesis in humans","volume":"51","author":"Browning","year":"2010","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.vph.2014.05.011_bb0490","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/ATVBAHA.110.214130","article-title":"Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans","volume":"30","author":"Persson","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.vph.2014.05.011_bb0495","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.atherosclerosis.2013.01.023","article-title":"PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells","volume":"227","author":"Levy","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2014.05.011_bb0245","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/ATVBAHA.108.181586","article-title":"Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia","volume":"29","author":"Le May","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2014.05.011_bb0250","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1161\/ATVBAHA.109.194191","article-title":"PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia","volume":"29","author":"Cariou","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2014.05.011_bb0500","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1743-7075-10-4","article-title":"Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets","volume":"10","author":"Cariou","year":"2013","journal-title":"Nutr Metab (Lond)"},{"key":"10.1016\/j.vph.2014.05.011_bb0260","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/hmg\/ddi128","article-title":"Evidence for effect of mutant PCSK9 on apolipoprotein b secretion as the cause of unusually severe dominant hypercholesterolaemia","volume":"14","author":"Sun","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.vph.2014.05.011_bb0265","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/ATVBAHA.110.204040","article-title":"Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control","volume":"30","author":"Herbert","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2014.05.011_bb0270","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.ATV.0000133684.77013.88","article-title":"Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9","volume":"24","author":"Ouguerram","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2014.05.011_bb0275","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1210\/en.2006-0098","article-title":"Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor","volume":"147","author":"Lambert","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.vph.2014.05.011_bb0280","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1194\/jlr.M400396-JLR200","article-title":"Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells","volume":"46","author":"Lalanne","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vph.2014.05.011_bb0285","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.trsl.2011.06.006","article-title":"Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people","volume":"158","author":"Sullivan","year":"2011","journal-title":"Transl Res"},{"key":"10.1016\/j.vph.2014.05.011_bb0290","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/ATVBAHA.112.250043","article-title":"Proprotein convertase subtilisin\/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor","volume":"32","author":"Sun","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2014.05.011_bb0295","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1042\/CS20110129","article-title":"Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia","volume":"121","author":"Brouwers","year":"2011","journal-title":"Clin Sci"},{"key":"10.1016\/j.vph.2014.05.011_bb0300","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.numecd.2012.11.008","article-title":"Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia","volume":"23","author":"Brouwers","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.vph.2014.05.011_bb0305","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbrc.2009.10.138","article-title":"PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion","volume":"390","author":"Langhi","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vph.2014.05.011_bb0310","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vph.2014.05.011_bb0315","doi-asserted-by":"crossref","first-page":"e64145","DOI":"10.1371\/journal.pone.0064145","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)","volume":"8","author":"Canuel","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vph.2014.05.011_bb0320","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/embor.2008.132","article-title":"PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1","volume":"9","author":"Jonas","year":"2008","journal-title":"EMBO Rep"},{"key":"10.1016\/j.vph.2014.05.011_bb0325","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hep.22911","article-title":"PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression","volume":"50","author":"Labonte","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.vph.2014.05.011_bb0330","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jcp.22130","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells","volume":"224","author":"Lan","year":"2010","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.vph.2014.05.011_bb0335","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jcp.21519","article-title":"Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9","volume":"217","author":"Ranheim","year":"2008","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.vph.2014.05.011_bb0340","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2014.05.011_bb0345","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.clinbiochem.2012.07.002","article-title":"Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects","volume":"45","author":"Kwakernaak","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.vph.2014.05.011_bb0350","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.jacc.2011.11.064","article-title":"Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin\/kexin type 9","volume":"59","author":"Melone","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2014.05.011_bb0355","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00018-012-0977-6","article-title":"PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling","volume":"69","author":"Kysenius","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.vph.2014.05.011_bb0360","first-page":"149","article-title":"Convergence of atherosclerosis and Alzheimer's disease: cholesterol, inflammation, and misfolded proteins","volume":"4","author":"Casserly","year":"2004","journal-title":"Discov Med"},{"key":"10.1016\/j.vph.2014.05.011_bb0365","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1073\/pnas.0600549103","article-title":"Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease","volume":"103","author":"Mahley","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vph.2014.05.011_bb0370","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.atherosclerosis.2009.06.023","article-title":"Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles","volume":"208","author":"Norata","year":"2010","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.vph.2014.05.011_bb0505","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11745-014-3895-6","article-title":"PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day","volume":"49","author":"Chen","year":"2014","journal-title":"Lipids"},{"key":"10.1016\/j.vph.2014.05.011_bb0380","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1194\/jlr.M006635","article-title":"PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain","volume":"51","author":"Liu","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vph.2014.05.011_bb0385","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1194\/jlr.M033969","article-title":"PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population","volume":"54","author":"Postmus","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.vph.2014.05.011_bb0390","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1152\/physrev.00033.2007","article-title":"LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies","volume":"88","author":"Lillis","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1016\/j.vph.2014.05.011_bb0395","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1082095","article-title":"LRP: role in vascular wall integrity and protection from atherosclerosis","volume":"300","author":"Boucher","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.vph.2014.05.011_bb0400","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MOL.0b013e32835e809c","article-title":"The low-density lipoprotein receptor-related protein 1 in inflammation","volume":"24","author":"May","year":"2013","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.vph.2014.05.011_bb0405","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1172\/JCI31929","article-title":"Adipocyte LDL receptor-related protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice","volume":"117","author":"Hofmann","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vph.2014.05.011_bb0410","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","article-title":"Gene inactivation of proprotein convertase subtilisin\/kexin type 9 reduces atherosclerosis in mice","volume":"125","author":"Denis","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2014.05.011_bb0415","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1194\/jlr.P023994","article-title":"Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia","volume":"53","author":"Huijgen","year":"2012","journal-title":"J Lipid Res"},{"issue":"6","key":"10.1016\/j.vph.2014.05.011_bb0510","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.metabol.2013.01.005","article-title":"Association of serum proprotein convertase subtilisin\/kexin type 9 with carotid intima media thickness in hypertensive subjects","volume":"62","author":"Lee","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.vph.2014.05.011_bb0425","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1073\/pnas.1214441110","article-title":"LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus","volume":"110","author":"Finkelshtein","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"10.1016\/j.vph.2014.05.011_bb0515","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia \u2014 the Mendel-2 randomized, controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.vph.2014.05.011_bb0520","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.vph.2014.05.011_bb0525","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2014.05.011_bb0445","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2014.05.011_bb0450","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2014.05.011_bb0455","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tips.2013.01.010","article-title":"Gene silencing approaches for the management of dyslipidaemia","volume":"34","author":"Norata","year":"2013","journal-title":"Trends Pharmacol Sci"},{"issue":"9911","key":"10.1016\/j.vph.2014.05.011_bb0530","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2013","journal-title":"Lancet"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189114001074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189114001074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T14:24:03Z","timestamp":1716819843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189114001074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1537189114001074"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2014.05.011","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2014.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2014.03.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}